rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Agilent Technologies, Inc.

A · NYSE

Health CareLife-science toolsLeading

A stood above a rising 150-day average in 25 of the last 52 weekly readings, including each of the last 10 weeks. It is 27.3% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
10 in a row
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$3.5M
Officials’ trades on record
38

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 25 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.4M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

38 disclosed lines: House 19, Senate 11, executive 8; 14 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k18 May 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k27 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$100k–$250k17 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k10 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$50k–$100k18 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k17 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k12 Feb 2026filed 14 May 2026
Arjun Mody Executive branch: Office of Government EthicsSocial Security Administrationsold$1k–$15k30 Jan 2026filed 10 Apr 2026
Julie Johnson House: U.S. House ClerkTX32soldjoint$1k–$15k23 Sep 2025filed 5 Aug 2026
Julie Johnson House: U.S. House ClerkTX32boughtjoint$1k–$15k23 Sep 2025filed 5 Aug 2026
Lisa C. McClain House: U.S. House ClerkMI09soldspouse$1k–$15k16 Jul 2025filed 13 Aug 2025
Lisa C. McClain House: U.S. House ClerkMI09boughtspouse$1k–$15k17 Jun 2025filed 13 Aug 2025

Insiders

Buy orders, 12 months0
Sale orders, 12 months6
Buyers · sellers0 · 3
WhoDidSharesTraded
Mikael DolstenDirectorsold634at $151.384 Sep 2026filed 9 Sep 2026
Mikael DolstenDirectorsold1,600at $135.4229 May 2026filed 2 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

Glenn S. Boehnlein Company insiderDirector · last 8 Sep 20260 · 0
Mikael Dolsten Company insiderDirector · last 4 Sep 20260 · 3
Jonah Prevost Kirkwood Company insiderSenior Vice President · last 26 Jun 20260 · 0
Padraig McDonnell Company insiderPresident and CEO · last 3 Jun 20260 · 18
Michael Steven Buckner Company insiderSenior Vice President · last 19 May 20260 · 0
Donald J. Trump Executive branchWhite House Office · last 18 May 20263 · 4
Simon May Company insiderSenior Vice President · last 8 May 20260 · 0
Meghan Henson Company insiderSenior Vice President · last 31 Mar 20260 · 0
Boon Hwee Koh Company insiderDirector · last 19 Mar 20261 · 8
Daniel K. Podolsky Company insiderDirector · last 19 Mar 20260 · 1
Dow R. Wilson Company insiderDirector · last 19 Mar 20260 · 0
George A. Scangos Company insiderDirector · last 19 Mar 20260 · 0

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Oct 202552.4%
Operating profit marginFY 2025 · to 31 Oct 202521.3%
Free cash flow marginFY 2025 · to 31 Oct 202516.6%
Return on capital employedFY 2025 · to 31 Oct 202514.2%
Cash conversionFY 2025 · to 31 Oct 2025120%
Debt to equityFY 2025 · to 31 Oct 20250.50×
Interest coverFY 2025 · to 31 Oct 202513.21×
Research spendFY 2025 · to 31 Oct 20256.5%
Share count trendFY 2025 · to 10 Dec 20250.2%
Cash and equivalentsFY 2025 · to 31 Oct 2025$1.8B
Free cash flowFY 2025 · to 31 Oct 2025$1.2B

Analyst forecasts

No analyst forecasts yet.